Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashlee Thomas

Physician Assistant, Medical Beckley, WV Physician Assistant

NPI 1093086233 CMS profile 10703352

101 S Eisenhower Dr, Beckley, WV 25801

Open in the dashboard

General payments

$4,593

259 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashlee Thomas of Beckley, WV is reported in the CMS Open Payments database as having received $4,593 across 259 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,305 76
2024 General $932 47
2023 General $1,201 67
2022 General $473 29
2021 General $681 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashlee Thomas
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Ashlee Thomas were reported at $1,305. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Ashlee Thomas Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $681 $156 $41–$563 $132
2022 $473 $185 $55–$649 $149
2023 $1,201 $199 $58–$717 $160
2024 $932 $206 $62–$740 $164
2025 $1,305 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teva Pharmaceuticals USA, Inc. $970 49 payments
  2. AbbVie, Inc. $595 34 payments
  3. Janssen Pharmaceuticals, Inc $490 24 payments
  4. Alkermes, Inc. $482 30 payments
  5. Lundbeck LLC $417 23 payments
  6. Indivior Inc. $190 10 payments
  7. Novo Nordisk Inc $185 11 payments
  8. E.R. Squibb & Sons, L.L.C. $166 13 payments
  9. Vanda Pharmaceuticals Inc. $132 5 payments
  10. Amgen Inc. $127 8 payments
  11. Other $838 52 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,518 258 payments
  2. Education $76 1 payment
Products named General payments · program years 2021–2025
  1. Austedo XR $690 37 payments
  2. LYBALVI $471 29 payments
  3. ARISTADA Cns $459 28 payments
  4. ARISTADA Cns $459 28 payments
  5. ARISTADA Cns $459 28 payments
  6. ARISTADA Cns $459 28 payments
  7. INVEGA SUSTENNA $391 19 payments
  8. VRAYLAR Neuroscience $327 16 payments
  9. ABILIFY MAINTENA $257 15 payments
  10. VRAYLAR Neuroscience $238 17 payments
  11. Other $2,883 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

4,512

Median for Physician Assistant: 241

Drug cost

$376,259

Median for Physician Assistant: $4,110

Branded share of claims

22.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 80 $113,608
Invega Sustenna Paliperidone Palmitate Brand 14 $45,646
Abilify Maintena Aripiprazole Brand 11 $31,660
Sublocade Buprenorphine Brand 14 $29,128
Rexulti Brexpiprazole Brand 15 $21,215
Vivitrol Naltrexone Microspheres Brand 12 $19,465
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 193 $16,667
Lurasidone Hcl Generic 73 $15,023
Suboxone Buprenorphine Hcl/Naloxone Hcl Brand 36 $13,685
Trintellix Vortioxetine Hydrobromide Brand 16 $9,115

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$15,020

Medicare's payments for the services billed

Medicare patients

85

Average age 55

Services billed

406

46 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Depression 55%
Arthritis 32%
COPD 29%
Diabetes 21%
Ischemic heart disease 16%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $312
$312 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $105
$105 14 —
REXULTI
  • Lundbeck LLC $67
  • Otsuka America Pharmaceutical, Inc. $32
$98 15 —
ABILIFY MAINTENA
  • Lundbeck LLC $91
$91 11 —
FANAPT
  • Vanda Pharmaceuticals Inc. $90
$90 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

259 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record